Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Adjuvanted and Non-Adjuvanted A/H2N3 Influenza Vaccine in Healthy Adults
NCT05875961Phase 1Completed
- Sponsor
- CSL Seqirus
- Start
- Jun 2023
- Primary completion
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in influenza (6 arms), sponsored by CSL Seqirus. Primary endpoints: Geometric mean titer of hemagglutination inhibition antibodies against homologous H2N3 strain at Day 43, Geometric mean titer of microneutralization antibodies against homologous H2N3 strain at Day 43 and 9 more. Started Jun 2023; status: completed.
02
Conditions
influenza
Beyond the preview
Go deeper on NCT05875961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05875961.